Tigermed Proposes New Three-Year Board Line-Up to Maintain Strategic Continuity

Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) just unveiled an update.

Hangzhou Tigermed Consulting Co., Ltd. has outlined the composition of its sixth board, proposing seven directors in line with Chinese company law and its articles of association, including one employee director. The company seeks shareholder approval to re-elect three executive directors and two independent non-executive directors, and to appoint one new independent non-executive director, each to serve a three-year term.

The proposal would maintain continuity in Tigermed’s leadership, with co-founder and chairman Dr. Ye Xiaoping continuing to oversee strategic planning and overall management. Dr. Ye’s significant shareholding, together with that of executive director Ms. Cao Xiaochun under an existing concert agreement, underscores concentrated ownership that may influence governance dynamics and strategic direction for stakeholders.

The most recent analyst rating on (HK:3347) stock is a Buy with a HK$61.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.

More about Hangzhou Tigermed Consulting Co., Ltd. Class H

Hangzhou Tigermed Consulting Co., Ltd. is a China-based contract research organization serving the biopharmaceutical industry. The company focuses on biopharmaceutical R&D support and related consulting services, leveraging its management expertise and strategic planning capabilities to serve domestic and international healthcare clients.

YTD Price Performance: -2.63%

Average Trading Volume: 2,034,252

Technical Sentiment Signal: Sell

Current Market Cap: HK$46.16B

For detailed information about 3347 stock, go to TipRanks’ Stock Analysis page.